According to an article from Ars, In a small Phase III clinical trial, the teens aged between 12 – 15 who has been vaccinated with Pfizer/ BioNTech mRNA vaccine were completely protected from COVID-19.

The vaccine appeared more effective at producing defensive immune responses in adolescents within ages 12–15 than in the 16-25 years old group, producing even higher levels of antibodies which were able to neutralize SARS-CoV-2.

The trial involved 2,260 adolescents ages 12 to 15, of which 1,131 were vaccinated and 1,129 received a placebo. There were 18 cases of symptomatic COVID-19 in the trial, all of which were in the placebo group. In today’s press release, the company announced that the vaccine demonstrated “100 percent efficacy.”